Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6831 USD | +1.94% | -14.24% | -51.55% |
Mar. 27 | Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating | MT |
Mar. 26 | Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.55% | 32.33M | - | ||
+73.17% | 12.34B | B- | ||
-18.74% | 7.96B | C+ | ||
+16.15% | 7.16B | C- | ||
+4.81% | 5.72B | B | ||
+5.99% | 5.03B | D+ | ||
+27.07% | 4.35B | - | ||
-21.67% | 3.99B | B- | ||
-40.82% | 2.21B | C | ||
+1.49% | 2.01B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LUCD Stock
- Ratings Lucid Diagnostics Inc.